The Daily Med

THE DAILY EDITIONMONDAY, 2 NOVEMBER 2026

CASE OF THE DAY · CLINICAL REASONING

Wheeze and hypotension minutes after a meal

A 34-year-old develops diffuse urticaria, tongue swelling, wheeze and light-headedness 5 minutes after eating a dessert containing peanut. Blood pressure is 78/46 mm Hg and pulse 128/min. What is the best immediate treatment?

Which intervention should be given first?

Drug Corner

Pharmacology in practice

GASTROENTEROLOGY

Omeprazole (oral)

Indication: Acid-related disorders, including reflux oesophagitis and peptic ulcer disease; H. pylori eradication only with combination therapy.
Mechanism: Inhibits gastric parietal-cell H+/K+-ATPase, suppressing the final step of acid secretion.
Interactions: Avoid with clopidogrel where possible: CYP2C19 inhibition reduces formation of its active metabolite; separating doses does not remove the interaction.
Important adverse effect: Common: headache, abdominal pain, diarrhoea, nausea or vomiting. Long-term use can cause hypomagnesaemia; reassess need and duration.
Dosing: Typical adult reflux oesophagitis regimen: 20 mg once daily for 4 weeks; indication, response and organ function determine regimen and duration.
Sources: Omeprazole 20 mg Capsules: Summary of Product Characteristics · EMA clopidogrel product information

Paper of the Day

Research, without the noise

Respiratory Medicine · COPD

Tozorakimab to Prevent COPD Exacerbations

Two replicate phase 3, placebo-controlled trials (OBERON and TITANIA) studied current or former smokers with COPD and a recent exacerbation despite stable inhaled maintenance therapy. Tozorakimab reduced annualized moderate or severe exacerbations in the overall populations: rate ratio 0.70 (95% CI 0.58–0.85) in OBERON and 0.71 (0.59–0.84) in TITANIA. Results were also significant among former smokers. The authors concluded that exacerbations were reduced; these trials establish an effect on exacerbation rate, not yet long-term mortality or universal suitability. Summary based on the accessible original abstract; supplementary methods were not reviewed.

Authors: F.C. Sciurba and Others

Published: 8 September 2026 · New England Journal of Medicine

DOI: 10.1056/NEJMoa2606998

Read the original paper at NEJM →

Journal Watch

What's new in medicine?

Critical Care · Oxygen therapy

Autonomous Oxygen Titration for Maintaining Normoxemia in Acutely Ill Adults: The SAVE-O2 AI Randomized Clinical Trial

In a 300-patient trial, autonomous oxygen titration improved target SpO₂ time (85% vs. 63%) and reduced hypoxemia versus usual care, though patient-centered outcomes were not established.

Infectious Diseases · Long-term care

Respiratory Outbreak Mitigation With Point-of-Care Testing in Long-Term Care: A Randomized Clinical Trial

In a 20-nursing home trial, on-site multiplex PCR didn't reduce respiratory outbreak number or size, but led to fewer ED transfers and faster antiviral initiation.

Diabetes · Cardiorenal care

Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry

In a registry study of 1,372 older Italian adults with diabetes and cardiorenal comorbidity, SGLT2i prescribing remained low despite a 2022 reimbursement change, describing prescribing trends rather than treatment effects.

Today's Topic

Build your clinical knowledge

Pulmonary Vascular Disease · PAH

Idiopathic PAH: confirm the haemodynamics before treatment

Diagnosis / Testing

Suspect pulmonary hypertension with otherwise unexplained exertional dyspnoea, syncope or right-heart findings. Echocardiography estimates probability; it does not establish PAH. Complete a structured work-up for lung and left-heart disease and associated conditions. Ventilation–perfusion scanning is recommended to exclude chronic thromboembolic PH; right-heart catheterization in an experienced PH centre confirms haemodynamics and classification.

Treatment / Care Decisions

The 2022 ESC/ERS definition of precapillary PH is mean pulmonary artery pressure >20 mmHg, pulmonary artery wedge pressure ≤15 mmHg and pulmonary vascular resistance >2 Wood units. Refer suspected PAH for expert assessment before PAH-specific therapy. In appropriately classified patients without cardiopulmonary comorbidities, initial endothelin-receptor antagonist plus PDE5-inhibitor therapy is recommended for low or intermediate risk; regimen and escalation are risk-based.

Risk Assessment / Prognosis / Epidemiology

Assess WHO functional class, exercise capacity, biomarkers, right-ventricular function and haemodynamics; right-ventricular failure drives clinical deterioration. Reassess after treatment initiation and during follow-up, ideally with a multiparameter risk tool. Pregnancy and planned procedures require specialist discussion because PAH carries substantial maternal and perioperative risk.

Pathophysiology / Basic Science

PAH is a precapillary pulmonary vascular disease with increased pulmonary vascular resistance. Endothelial dysfunction, vasoconstriction and vascular remodeling raise right-ventricular afterload; progressive right-ventricular dysfunction can lead to systemic congestion and low cardiac output. Treatment targets several pathways, including endothelin, nitric oxide–cGMP and prostacyclin.

Further reading: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.